Literature DB >> 33546051

Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence: A protocol for a Bayesian network meta analysis.

Yuli Sun1,2, Zhaofeng Tan2, Zhenyuan Jiang1, Min Li2, Weiqin Wang2, Yaoyao Huang1, Jianguang Sun1.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease is a common reason for chronic liver disease in children and adults. The increasing incidence of the disease has become one of the most critical public health problems in the 21st century, closely related to genetic and environmental factors. So far, apart from changing lifestyle and diet, modern medicine still lacks effective treatment measures. Chinese patent medicine has the advantages of apparent curative effect, overall regulation and fewer side effects. However, there is a lack of research on the simultaneous comparison of various Chinese patent medicines. Therefore, we used a reticular meta-analysis to indirectly compare the efficacy and safety of different oral Chinese patent medicines through standard reference.
METHOD: We will conduct a comprehensive and systematic search of Chinese and English databases from the beginning to December 2020. All randomized controlled trials (RCTs) of oral Chinese patent medicine for NAFLD in children will be searched. The 2 researchers then independently filter the retrieved literature, extract the data according to the data extraction table and assess the risk of bias. We will perform a pair of meta-analyses and a Bayesian network meta-analysis. STATA and Win BUGS software will be used for data analysis.
RESULTS: This study will thoroughly compare and analyze the differences in the efficacy of all kinds of TCPM in NAFLD treatment in childhood or adolescence.
CONCLUSION: This study will provide reference and evidence support for clinical drug selection optimization. ETHICS AND DISSEMINATION: This study does not require ethical approval. INPLASY REGISTRATION NUMBER: 2020120068.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33546051      PMCID: PMC7837984          DOI: 10.1097/MD.0000000000024277

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  25 in total

1.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

2.  Risk factors for progression of and treatment options for NAFLD in children.

Authors:  Phillipp Hartmann; Bernd Schnabl
Journal:  Clin Liver Dis (Hoboken)       Date:  2018-01-31

Review 3.  Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment.

Authors:  Anna Alisi; Stefano Cianfarani; Melania Manco; Carlo Agostoni; Valerio Nobili
Journal:  Ann Med       Date:  2011-02-28       Impact factor: 4.709

Review 4.  Extrahepatic Complications of Nonalcoholic Fatty Liver Disease.

Authors:  Kristina R Chacko; John Reinus
Journal:  Clin Liver Dis       Date:  2016-02-18       Impact factor: 6.126

5.  Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study.

Authors:  Jacob Alexander; Michael Torbenson; Tsung-Teh Wu; Matthew M Yeh
Journal:  J Gastroenterol Hepatol       Date:  2013-05       Impact factor: 4.029

Review 6.  PNPLA3 I148M polymorphism and progressive liver disease.

Authors:  Paola Dongiovanni; Benedetta Donati; Roberta Fares; Rosa Lombardi; Rosellina Margherita Mancina; Stefano Romeo; Luca Valenti
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

Review 7.  Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis.

Authors:  Paola Dongiovanni; Stefano Romeo; Luca Valenti
Journal:  Biomed Res Int       Date:  2015-07-27       Impact factor: 3.411

Review 8.  Obese children with fatty liver: Between reality and disease mongering.

Authors:  Giusy Ranucci; Maria Immacolata Spagnuolo; Raffaele Iorio
Journal:  World J Gastroenterol       Date:  2017-12-21       Impact factor: 5.742

9.  Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents.

Authors:  Debbie A Lawlor; Mark Callaway; Corrie Macdonald-Wallis; Emma Anderson; Abigail Fraser; Laura D Howe; Chris Day; Naveed Sattar
Journal:  J Clin Endocrinol Metab       Date:  2014-01-28       Impact factor: 5.958

Review 10.  A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence.

Authors:  Jonathan L Temple; Paul Cordero; Jiawei Li; Vi Nguyen; Jude A Oben
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

View more
  1 in total

1.  Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease.

Authors:  Zheng Xu; Fan-Wei Wu; Xuan Niu; Xiao-Peng Lu; Yan-Rong Li; Shu-Ting Zhang; Jun-Zhao Ou; Xue-Mei Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.